VYGR fundamentals
Key facts
Market capitalization188.26 MUSD
Basic EPS (TTM)−1.13USD
Founded2013
CEOAlfred W. Sandrock
Websitevoyagertherapeutics.com
About
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−600%
−400%
−200%
0%
200%
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−35.00 M
0.00
35.00 M
70.00 M
105.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
VYGR does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company